We expect BCP to report a net profit of Bt2.2b for 1Q25. Excluding extra items, core profit could fall 55% yoy and 14% qoq to Bt1.6b. However, we still like BCP due to the expected earnings recovery from 2Q25 onwards, supported by its restructuring plan to acquire BSRC. Maintain BUY. Target price: Bt45.00.
KEY HIGHLIGHTS Results Home Product Center (HMPRO TB/HOLD/Bt8.25/Target: Bt10.00) 1Q25: Flattish yoy earnings momentum. Update Bangchak Corporation (BCP TB/BUY/Bt35.50/Target: Bt45.00) 1Q25 results preview: Expect a soft quarter, but remain positive on the long-term outlook. Bangchak Sriracha (BSRC TB/BUY/Bt5.35/Target: Bt7.00) 1Q25 results preview: Expect slim core and net profits. SCG Packaging (SCGP TB/HOLD/Bt14.00/Target: Bt13.20) 2Q25 net profit expected to contin...
GREATER CHINA Results China Construction Bank (939 HK/HOLD/HK$6.79/Target: HK$7.00): 1Q25: Earnings miss due to weaker NIM and fee income; tariff risk is limited. Downgrade to HOLD. China Longyuan Power (916 HK/HOLD/HK$6.10/Target: HK$6.60): 1Q25: In line; cautious outlook amid rising curtailment rates and upcoming policy shift. China Merchants Bank (3968 HK/BUY/HK$44.50/Target: HK$49.00): 1Q25: Earnings down 2.1% yoy on weaker trading gains. Estun Automation (002747 CH/SELL/Rmb19.17/Target: Rmb...
GREATER CHINA Sector Automobile: Weekly: PV sales rebound wow but remain low due to wait-and-see sentiment. Maintain MARKET WEIGHT on the sector. Top BUYs: Geely, CATL, Fuyao and Desay. Renewable Energy: Solar energy equipment: Policy-driven installation rush to support prices; milder module shipment growth in 2025. Results Alibaba Group (9988 HK/BUY/HK$120.90/Target: HK$150.00): 3QFY25: CMR beat; all-in AI; capex in next three years to exceed that of the past decade. Lenovo Group (992 HK/BUY/HK...
BCP posted a 4Q24 net profit of Bt17m. Excluding extraordinary items, BCP’s core profit could surge 153% qoq to Bt1.8b, 13% above our estimate. BCP’s 2024 core profit fell 38% yoy to Bt6.1b due to lower GRM in 2024. We believe BCP’s profit will outperform peers’ in 1Q25 due to higher diesel production proportion with lower crude premiums. BCP announced a tender offer for the remaining 18.3% stake in BSRC with completion expected in Nov 25. Maintain BUY. Target price: Bt45.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt36.50/Target: Bt45.00) 4Q24: Above expectations; earnings projected to outperform peers’ in 2025. Bangchak Sriracha (BSRC TB/BUY/Bt4.94/Target: Bt8.00) 4Q24: Results in line with expectations. GFPT (GFPT TB/BUY/Bt9.15/Target: Bt13.00) 4Q24: Earnings miss expectations; deep discount valuation. True Corporation (TRUE TB/BUY/Bt12.80/Target: Bt14.50) 4Q24: Results below our...
We expect BCP to report a net profit of Bt220m for 4Q24. Excluding extra items, core profit could jump 124% qoq to Bt1.6b. We like BCP for its strong earnings outlook in 2025. We foresee opportunities to accumulate the stock. Maintain BUY. Target price: Bt45.00
GREATER CHINA Strategy Small-Mid Cap Monthly: Countdown to Plover Bay’s 2024 results: Eyeing final dividend and 2025 outlook. Sector Automobile: Weekly: OEMs post upbeat January sales. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao and Desay. Update Aier Eye Hospital Group (300015 CH/HOLD/Rmb12.71/Target: Rmb13.80): Expecting slower growth amid weaker demand, yet outperforming peers. Downgrade to HOLD. INDONESIA Results XL Axiata (EXCL IJ/BUY/Rp2,290/Target: Rp3,300): 4Q24: NPAT jumps 93%...
GREATER CHINA Strategy Alpha Picks: December Conviction Calls Add Desay, Meituan, Mengniu, Tencent, and Trip.com to our BUY list. Take profit from CATL. Update CR Mixc Lifestyle (1209 HK/BUY/HK$29.20/Target: HK$32.15) Takeaways from reverse roadshow in Shenzhen. China Resources Land (1109 HK/BUY/HK$23.25/Target:HK$32.40) Takeaways from reverse roadshow in Shenzhen. Small/Mid Cap Highlights Regina Miracle (2199 HK/Not Rated/HK$2....
BCP’s 3Q24 net loss was Bt2.1b (3Q23: gains Bt11.1b; 2Q24: gains Bt1.8b) due to an inventory loss of Bt5.1b. Excluding extra items, core profit was Bt711m, down 81% yoy but up 2,122% qoq. Both core profit and net loss were in line with our estimates. We think the 22% ytd decline in the share price offers an opportunity to buy on weakness. BCP now trades at only 4.6x 2025F PE with potential to provide a 5.6% dividend yield for 2025. Maintain BUY. Target price: Bt45.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt33.00/Target: Bt45.00) 3Q24: Earnings hurt by weaker GIM and inventory loss Bangchak Sriracha (BSRC TB/BUY/Bt7.10/Target: Bt9.00) 3Q24: Results better than expected. Berli Jucker (BJC TB/BUY/Bt23.40/Target: Bt28.00) 3Q24: Earnings in line; expect 4Q24 EBIT to continue to improve yoy. Bumrungrad Hospital (BH TB/BUY/Bt262.00/Target: Bt303.00) 3Q24: Di...
GREATER CHINA Economics Trade Surprising beat on exports. Sector Automobile Weekly: Trump’s tariff to reshape China automobile supply chain. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao Glass and Desay SV. Results Galaxy Entertainment Group (27 HK/BUY/HK$36.35/Target: HK$46.00) 3Q24: EBITDA decline due to higher reinvestmen...
GREATER CHINA Results China Construction Bank (939 HK/BUY/HK$5.43/Target: HK$6.00): 2Q24: Earnings decline narrowed to 1.4% on strong trading income. China Merchants Bank. (3968 HK/BUY/HK$32.35/Target: HK$42.00): 1H24: Still waiting to thrive. China Tourism Group Duty Free (601888 CH/BUY/Rmb58.93/Target: Rmb83.40): 2Q24: Slight earnings miss; Hainan duty-free business under pressure; airport business recovery underway. Kingmed Diagnostics (603882 CH/BUY/Rmb25.66/Target: Rmb35.00): 1H24: Signific...
BCP reported a 2Q24 net profit of Bt1.8b (+298% yoy, -25% qoq), in line with our estimate. Excluding inventory and other items, core profit was Bt32m. We believe BCP’s earnings will remain strong in 2H24. We think that the 23% ytd decline in the share price offers an opportunity to buy on weakness. We expect a 6.0% dividend yield for 2024. Maintain BUY. Target price: Bt45.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt33.50/Target: Bt45.00) 2Q24: Weak 2Q24; expect significant improvement in 3Q24. Bangchak Sriracha (BSRC TB/BUY/Bt6.80/Target: Bt9.00) 2Q24: Weak results as expected. LPN Development (LPN TB/SELL/Bt2.98/Target: Bt2.40) 2Q24: Results below expectation; unexciting business outlook. Major Cineplex (MAJOR TB/BUY/Bt13.60/Target: Bt18.00) ...
GREATER CHINA Sector Automobile: Weekly: PV sales rebound by 17% yoy on increased subsidies. Maintain MARKET WEIGHT. Top BUYs: CATL and Desay SV. Top SELL: XPeng. Shipping and Ports: Freight rates peaked but forward decline is priced in. Maintain MARKET WEIGHT and upgraded CSH to BUY. Results Jonjee Hi-Tech Industrial & Commercial (600872 CH/BUY/Rmb19.80/Target: Rmb27.00): 2Q24: Results miss expectations; condiment business under pressure. Kweichow Moutai (600519 CH/BUY/Rmb1,430.69/Target: Rmb2,...
We expect BCP to post 57% yoy and 86% qoq weaker core profit of Bt480m in 2Q24. Including inventory impact, BCP is likely to post a net profit of around Bt1.9b in 2Q24 (up 304% yoy but down 24% qoq). However, we believe earnings will return to normal in 2H24, backed by a strong utilisation rate after resuming operations at Phra Khanong and the peak season for the renewable business. Maintain BUY. Target price: Bt45.00.
KEY HIGHLIGHTS Results SCGP (SCGP TB/BUY/Bt28.50/Target: Bt41.00) 2Q24: Core profit within expectations. Update Bangchak Corporation (BCP TB/BUY/Bt41.25/Target: Bt45.00) 2Q24 preview: Expect weak operating numbers due to 27 days of scheduled maintenance. Bangchak Sriracha (BSRC TB/BUY/Bt8.70/Target: Bt10.00) 2Q24 preview: Earnings still in the black.
GREATER CHINA Initiate Coverage CSPC Innovation Pharmaceutical Co (300765 CH/BUY/Rmb24.40/Target: Rmb33.00): Transforming into a drug innovator with over 200% earnings CAGR in 2024-26. INDONESIA Update Dayamitra Telekomunikasi (MTEL IJ/BUY/Rp690/Target: Rp810): Expect 52% yoy growth in 2024 fibre optic revenue; exploring non-terrestrial network technology’s potential; maintain BUY. MALAYSIA Update Top Glove (TOPG MK/BUY/RM1.24/Target: RM1.45): Against a backdrop of favourable tailwinds, we hav...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.